JP2009536221A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536221A5
JP2009536221A5 JP2009510118A JP2009510118A JP2009536221A5 JP 2009536221 A5 JP2009536221 A5 JP 2009536221A5 JP 2009510118 A JP2009510118 A JP 2009510118A JP 2009510118 A JP2009510118 A JP 2009510118A JP 2009536221 A5 JP2009536221 A5 JP 2009536221A5
Authority
JP
Japan
Prior art keywords
alkyl
tetrazole
conr
phenyl
och
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009510118A
Other languages
English (en)
Japanese (ja)
Other versions
JP5561720B2 (ja
JP2009536221A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/068342 external-priority patent/WO2007131219A2/en
Publication of JP2009536221A publication Critical patent/JP2009536221A/ja
Publication of JP2009536221A5 publication Critical patent/JP2009536221A5/ja
Application granted granted Critical
Publication of JP5561720B2 publication Critical patent/JP5561720B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009510118A 2006-05-05 2007-05-07 肥満及び糖尿病を含む心臓血管障害を治療するために有用なカンナビノイド受容体アンタゴニスト/インバ−スアゴニスト Expired - Fee Related JP5561720B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79800106P 2006-05-05 2006-05-05
US60/798,001 2006-05-05
PCT/US2007/068342 WO2007131219A2 (en) 2006-05-05 2007-05-07 Cannabinoid receptor antagonists/inverse agonists

Publications (3)

Publication Number Publication Date
JP2009536221A JP2009536221A (ja) 2009-10-08
JP2009536221A5 true JP2009536221A5 (zh) 2010-06-24
JP5561720B2 JP5561720B2 (ja) 2014-07-30

Family

ID=38668620

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009510118A Expired - Fee Related JP5561720B2 (ja) 2006-05-05 2007-05-07 肥満及び糖尿病を含む心臓血管障害を治療するために有用なカンナビノイド受容体アンタゴニスト/インバ−スアゴニスト

Country Status (9)

Country Link
US (4) US7482470B2 (zh)
EP (1) EP2023920B1 (zh)
JP (1) JP5561720B2 (zh)
CN (1) CN101484161A (zh)
AU (1) AU2007247878B2 (zh)
CA (1) CA2651385C (zh)
ES (1) ES2389569T3 (zh)
IL (1) IL195071A (zh)
WO (1) WO2007131219A2 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7655685B2 (en) 2007-11-02 2010-02-02 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
WO2009085198A2 (en) * 2007-12-20 2009-07-09 Indigene Pharmaceuticals, Inc. Combination of metformin r-(+)-lipoate and antiobesity agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011044370A1 (en) 2009-10-07 2011-04-14 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
AU2011329636B2 (en) * 2010-11-18 2016-05-19 Jenrin Discovery Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8680131B2 (en) 2012-07-25 2014-03-25 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
JP6272626B2 (ja) 2012-11-13 2018-01-31 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ カンナビノイド受容体媒介性化合物
US11155521B2 (en) 2012-11-13 2021-10-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
CN106660968B (zh) 2014-05-09 2020-02-07 美国政府(由卫生和人类服务部的部长所代表) 吡唑衍生物及其作为大麻素受体介体的用途
KR20210152312A (ko) 2020-06-08 2021-12-15 주식회사 종근당 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물
WO2023089612A1 (en) 2021-11-19 2023-05-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Peripheral cb1 receptor antagonists for treatment of lower urinary tract symptoms (luts)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236137T1 (de) 1996-02-02 2003-04-15 Merck & Co Inc Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
ATE293963T1 (de) 1996-02-02 2005-05-15 Merck & Co Inc Verfahren zur behandlung von diabetes und verwandter krankheitszustände.
JP2002515865A (ja) 1996-02-02 2002-05-28 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
ATE245622T1 (de) 1996-02-02 2003-08-15 Merck & Co Inc Antidiabetische mittel
DZ3335A1 (fr) * 2000-03-23 2001-09-27 Solvay Pharm Bv Derives de 4,5-dihydro-1h-pyrazole ayant une activite antagoniste de cb1
JP4313671B2 (ja) * 2001-09-21 2009-08-12 ソルベイ・フアーマシユーチカルズ・ベー・ブイ Cb1−拮抗活性を有する新規4,5−ジヒドロ−1h−ピラゾール誘導体
CA2442245C (en) * 2001-09-21 2010-03-30 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
US7655685B2 (en) 2007-11-02 2010-02-02 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

Similar Documents

Publication Publication Date Title
JP2009536221A5 (zh)
JP2009529540A5 (zh)
JP2010511721A5 (zh)
JP2007534702A5 (zh)
JP2006151984A5 (zh)
JP2011520815A5 (zh)
JP2009504764A5 (zh)
JP2018135343A5 (zh)
JP2005523922A5 (zh)
JP2012505871A5 (zh)
JP2008510770A5 (zh)
JP2009536660A5 (zh)
JP2004516314A5 (zh)
JP2010520851A5 (zh)
JP2010515731A5 (zh)
JP2013510860A5 (zh)
JP2008520662A5 (zh)
JP2012515776A5 (zh)
JP2011037841A5 (zh)
CA2569850A1 (en) 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2,3-d] pyrimidine derivatives and related compounds for the treatment of cancer
JP2011522789A5 (zh)
JP2008545631A5 (zh)
JP2012006912A5 (ja) トリアゾール誘導体
JP2019529419A5 (zh)
JP2008542386A5 (zh)